Despite US tariff concerns, India's pharmaceutical exports are projected to double to $65 billion by 2030. This growth is ...

Bank of Baroda reported net profit at Rs 4,541 crore for Q1 FY26. This marks a 2 percent rise from the Rs 4,458 crore net ...

Cipla Ltd (BOM:500087) reports robust financial performance with significant milestones in India and strategic advancements in the US market.

Balkrishna Industries, Lodha Developers, Whirlpool, ZEN Technologies, and SBFC Finance are also to release their April-June ...

Total Income from operations rose to Rs 6,957 crore for the June quarter as compared with Rs 6,694 crore in the year-ago ...

New Delhi, Jul 25 (PTI) Drug major Cipla on Friday reported a 10 per cent increase in its consolidated profit after tax to ₹ 1,298 crore for the first quarter ended June 30, 2025, aided by robust ...

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

Porvorim: Blaming govt for doing little to ensure employment opportunities for locals, legislators on Friday said that ...

Indian pharmaceutical company, Cipla, aims to reach $1 billion in US sales by FY27, driven by upcoming product launches.

Cipla reported a 10% rise in Q1 PAT to ?1,298 crore, driven by India, Europe, and Africa sales. Revenue grew to ?6,957 crore despite a North America dip.

Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in ...